41598-57-6

Basic information

• Product Name: ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate
• Synonyms: ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate
• CAS NO: 41598-57-6
• Molecular Formula: C11H10ClNO3
• Molecular Weight: 239.655
• Mol File: 41598-57-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate(41598-57-6)
• EPA Substance Registry System: ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate(41598-57-6)

Safety Data

• Hazardous Substances Data: 41598-57-6(Hazardous Substances Data)

Upstream product

• 31163-14-1 diethyl 2-((6-chloro-3-(ethoxycarbonyl)pyridin-2-yl)methyl)-malonate 
• 1039037-16-5 5-ethyl 1-methyl 4-(1-amino-ethylidene)-pent-2-enedioate 
• 3424-43-9 ethyl 6-hydroxy-2-methylnicotinate 
• 31163-13-0 ethyl 2-(bromomethyl)-6-chloronicotinate 
• 3424-43-9 ethyl 2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 53256-25-0 (2E,4Z)-5-ethyl 1-methyl 4-(1-aminoethylidene)pent-2-enedioate 
• 31163-12-9 ethyl 6-chloro-2-methylnicotinate 

Downstream Products

• 1359669-60-5 C₂₃H₂₁NO₂ 
• 1359669-62-7 diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate 
• 1359668-78-2 2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ol 
• 1359668-80-6 {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}acetic acid 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Preparation method of 2-methoxy-6, 7-dihydro-5H-cyclopenta [b] pyridine-5-one

The invention relates to a preparation method of 2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-5-one. According to the preparation method, ethyl acetoacetate is used as a starting raw material, and anovel target product 2-methoxy-6, 7-dihydro-5H-cyclopenta[b]pyridine-5-one is prepared through nine steps of reactions including dehydration, addition, cyclization, chlorination, bromination, substitution, cyclization again, decarboxylation and etherification. The preparation method of the novel target product is simple and efficient. The purity of the novel target product prepared by the methoddisclosed by the invention reaches over 99.0%.

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists

The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl} propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy} -2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.